Jump to main content.


Acrolein Quickview (CASRN 107-02-8)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Acrolein

File First On-Line: 09/07/1988; Last Significant Revision: 06/03/2003

Category (section)
Status
Last Revised
Oral RfD Assessment On-line 06/03/2003
Inhalation RfC Assessment On-line 06/03/2003
Carcinogenicity Assessment On-line 06/03/2003
Synonyms
  • 107-02-8
  • Acraldehyde
  • Acrolein
  • Acrylaldehyde
  • 2-Propenal
  • Allyl aldehyde
  • Ethylene aldehyde
  • Propenal
  • Prop-2-en-l-al
Acrolein Source Documents
Revision History
Date Section Description
04/01/1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect
Point of Departure*
UF RfD
Decreased survival NOAEL : 0.05 mg/kg-day 100 5 x10-4 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page


Reference Concentration for Chronic Inhalation Exposure (RfC)

Critical Effect
Point of Departure*
UF RfC
Nasal lesions LOAEL (HEC): 0.02 mg/m3 1000 2x10-5 mg/m3

* The Point of Departure listed serves as a basis from which the Inhalation RfC was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • Data are inadequate for an assessment of human carcinogenic potential
  • Weight-of-Evidence Narrative:
    • Under the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), the potential carcinogenicity of acrolein cannot be determined because the existing data are inadequate for an assessment of human carcinogenic potential for either the oral or inhalation route of exposure. There are no adequate human studies of the carcinogenic potential of acrolein. Collectively, experimental studies provide inadequate evidence that acrolein causes cancer in laboratory animals.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

  • Not Assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

  • Not Assessed under the IRIS Program.

Top of page


Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research


Local Navigation


Jump to main content.